NO20030625L - Kinolinderivater med VEGF-inhiberende aktivitet - Google Patents

Kinolinderivater med VEGF-inhiberende aktivitet

Info

Publication number
NO20030625L
NO20030625L NO20030625A NO20030625A NO20030625L NO 20030625 L NO20030625 L NO 20030625L NO 20030625 A NO20030625 A NO 20030625A NO 20030625 A NO20030625 A NO 20030625A NO 20030625 L NO20030625 L NO 20030625L
Authority
NO
Norway
Prior art keywords
inhibitory activity
quinoline derivatives
vegf inhibitory
vegf
quinoline
Prior art date
Application number
NO20030625A
Other languages
English (en)
Other versions
NO20030625D0 (no
NO326315B1 (no
Inventor
Laurent Francois And Hennequin
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20030625L publication Critical patent/NO20030625L/no
Publication of NO20030625D0 publication Critical patent/NO20030625D0/no
Publication of NO326315B1 publication Critical patent/NO326315B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20030625A 2000-08-09 2003-02-07 Kinolinderivater, fremgangsmate for fremstilling av disse, farmasoytisk preparat inneholdende slike samt anvendelse av disse ved fremstilling av medikament for behandling av sykdom. NO326315B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00402254 2000-08-09
PCT/GB2001/003553 WO2002012226A1 (en) 2000-08-09 2001-08-08 Quinoline derivatives having vegf inhibiting activity

Publications (3)

Publication Number Publication Date
NO20030625L true NO20030625L (no) 2003-02-07
NO20030625D0 NO20030625D0 (no) 2003-02-07
NO326315B1 NO326315B1 (no) 2008-11-10

Family

ID=8173805

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20030625A NO326315B1 (no) 2000-08-09 2003-02-07 Kinolinderivater, fremgangsmate for fremstilling av disse, farmasoytisk preparat inneholdende slike samt anvendelse av disse ved fremstilling av medikament for behandling av sykdom.

Country Status (14)

Country Link
US (2) US7371765B2 (no)
EP (1) EP1313726A1 (no)
JP (1) JP2004505964A (no)
KR (1) KR20030036686A (no)
CN (1) CN1315822C (no)
AU (2) AU2001276536B2 (no)
BR (1) BR0113056A (no)
CA (1) CA2415469A1 (no)
IL (2) IL153947A0 (no)
MX (1) MXPA03000252A (no)
NO (1) NO326315B1 (no)
NZ (1) NZ523358A (no)
WO (1) WO2002012226A1 (no)
ZA (1) ZA200300217B (no)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2262935C2 (ru) 1999-02-10 2005-10-27 Астразенека Аб Производные хиназолина в качестве ингибиторов ангиогенеза
NZ518028A (en) 1999-11-05 2004-03-26 Astrazeneca Ab Quinazoline derivatives as VEGF inhibitors
JP2003525897A (ja) 2000-03-06 2003-09-02 アストラゼネカ アクチボラグ 治 療
IL151626A0 (en) * 2000-04-07 2003-04-10 Astrazeneca Ab Quinazoline compounds
PT1474420E (pt) 2002-02-01 2012-05-10 Astrazeneca Ab Compostos de quinazolina
TW200400034A (en) 2002-05-20 2004-01-01 Bristol Myers Squibb Co Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors
PL215161B1 (pl) 2002-11-04 2013-10-31 Astrazeneca Ab Pochodne chinazoliny, sposób ich wytwarzania, kompozycje farmaceutyczne je zawierajace oraz ich zastosowanie
GEP20084572B (en) * 2003-12-23 2008-12-25 Pfizer Novel quinoline derivatives
AU2008202205B2 (en) * 2003-12-23 2009-09-10 Pfizer Inc. Novel quinoline derivatives
JP4585978B2 (ja) * 2005-03-03 2010-11-24 参天製薬株式会社 キノリルアルキルチオ基を有する新規環式化合物
MX2008001838A (es) 2005-08-08 2008-04-09 Pfizer Sales y polimorfos de un inhibidor de vegf-r.
US20080190689A1 (en) * 2007-02-12 2008-08-14 Ballard Ebbin C Inserts for engine exhaust systems
CA2729303A1 (en) 2008-06-30 2010-01-14 Angioblast Systems, Inc. Treatment of eye diseases and excessive neovascularization using a combined therapy
CN101723894B (zh) * 2009-12-03 2011-12-28 南京大学 N-喹啉酰胺类衍生物及其制法与用途
US9604963B2 (en) 2011-03-04 2017-03-28 Glaxosmithkline Intellectual Property Development Limited Amino-quinolines as kinase inhibitors
TWI547494B (zh) 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之胺基喹唑啉類
AR092530A1 (es) 2012-09-13 2015-04-22 Glaxosmithkline Llc Compuesto de amino-quinolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
AR092529A1 (es) 2012-09-13 2015-04-22 Glaxosmithkline Llc Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
AU2014216178B2 (en) 2013-02-15 2018-06-28 KALA BIO, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
EP3763710A1 (en) 2013-02-20 2021-01-13 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
BR112015019624A2 (pt) 2013-02-21 2017-07-18 Glaxosmithkline Ip Dev Ltd quinazolinas como inibidores de quinase
NZ719185A (en) 2013-11-01 2017-11-24 Kala Pharmaceuticals Inc Crystalline forms of therapeutic compounds and uses thereof
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CN106046007B (zh) * 2015-04-07 2019-02-05 广东众生睿创生物科技有限公司 酪氨酸激酶抑制剂及包含该酪氨酸激酶抑制剂的药物组合物
WO2017139417A1 (en) 2016-02-08 2017-08-17 Vitrisa Therapeutics, Inc. Compositions with improved intravitreal half-life and uses thereof
CA3036340A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CA3036065A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3509422A4 (en) 2016-09-08 2020-05-20 Kala Pharmaceuticals, Inc. CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
WO2020176599A1 (en) 2019-02-27 2020-09-03 The Regents Of The University Of California Azepino-indoles and other heterocycles for treating brain disorders
WO2021143928A1 (zh) * 2020-01-19 2021-07-22 正大天晴药业集团股份有限公司 用于治疗类风湿性关节炎的喹啉衍生物

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US36256A (en) * 1862-08-19 Improvement in sewing-m ach ines
US3755332A (en) * 1971-07-01 1973-08-28 Ciba Geigy Corp Substituted 4 indazolaminoquinolines
IL81307A0 (en) 1986-01-23 1987-08-31 Union Carbide Agricult Method for reducing moisture loss from plants and increasing crop yield utilizing nitrogen containing heterocyclic compounds and some novel polysubstituted pyridine derivatives
IL89029A (en) 1988-01-29 1993-01-31 Lilly Co Eli Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them
DE69222637T2 (de) * 1991-05-10 1998-02-26 Rhone Poulenc Rorer Int Bis mono- und bicyclische aryl- und heteroarylderivate mit inhibierender wirkung auf die egf und/oder pdgf-rezeptor tyrosinkinase
US5480883A (en) * 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
IL117620A0 (en) 1995-03-27 1996-07-23 Fujisawa Pharmaceutical Co Heterocyclic compounds processes for the preparation thereof and pharmaceutical compositions containing the same
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
WO1997017329A1 (fr) 1995-11-07 1997-05-15 Kirin Beer Kabushiki Kaisha Derives de quinoline et derives de quinazoline inhibant l'autophosphorylation d'un recepteur de facteur de croissance originaire de plaquettes, et compositions pharmaceutiques les contenant
AR007857A1 (es) 1996-07-13 1999-11-24 Glaxo Group Ltd Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen.
ATE300521T1 (de) * 1996-09-25 2005-08-15 Astrazeneca Ab Chinolin-derivate die den effekt von wachstumsfaktoren wie vegf vezögern
DK0882717T3 (da) 1996-10-01 2010-12-13 Kyowa Hakko Kirin Co Ltd Nitrogenholdige heterocykliske forbindelser
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
CA2291709A1 (en) 1997-05-30 1998-12-03 Merck & Co., Inc. Novel angiogenesis inhibitors
US6162804A (en) * 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
GB9721437D0 (en) 1997-10-10 1997-12-10 Glaxo Group Ltd Heteroaromatic compounds and their use in medicine
GB9800569D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
ES2211175T3 (es) * 1998-09-29 2004-07-01 Wyeth Holdings Corporation Inhibidores de proteinas de tipo tirosina quinasas a base de 3-cianoquinolinas sustituidas.
GB2345486A (en) 1999-01-11 2000-07-12 Glaxo Group Ltd Heteroaromatic protein tyrosine kinase inhibitors
UA71945C2 (en) 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
JP3270834B2 (ja) 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa

Also Published As

Publication number Publication date
NZ523358A (en) 2004-09-24
EP1313726A1 (en) 2003-05-28
US20080312273A1 (en) 2008-12-18
CN1315822C (zh) 2007-05-16
AU7653601A (en) 2002-02-18
AU2001276536B9 (en) 2002-02-18
WO2002012226A1 (en) 2002-02-14
US20030199491A1 (en) 2003-10-23
IL153947A0 (en) 2003-07-31
US7371765B2 (en) 2008-05-13
KR20030036686A (ko) 2003-05-09
ZA200300217B (en) 2004-04-08
NO20030625D0 (no) 2003-02-07
CN1446212A (zh) 2003-10-01
IL153947A (en) 2008-12-29
BR0113056A (pt) 2003-07-08
AU2001276536B2 (en) 2007-01-04
JP2004505964A (ja) 2004-02-26
MXPA03000252A (es) 2003-06-06
CA2415469A1 (en) 2002-02-14
NO326315B1 (no) 2008-11-10

Similar Documents

Publication Publication Date Title
NO20030625D0 (no) Kinolinderivater med VEGF-inhiberende aktivitet
CY2012026I2 (el) Παραγωγα κουιναζολινης ως αναστολεις vegf
NO20032596L (no) Heterosykliske etersubstituerte imidazokinoliner
ATE422495T1 (de) Antibakterielle naphthydrin- und quinolinderivate
NO20031097D0 (no) Kinolinderivater
PT1206469E (pt) Fenil-oxazolidinonas substituidas heterociclicas antibacterianas
DE60209734D1 (de) Tetrahydrochinolin-derivate
IS8439A (is) Nýjar kínólín afleiður
DE60302336D1 (de) Neue pyridin- und quinolin-derivate
DE60012154D1 (de) Zange
DE60011932D1 (de) Neuartige phenylalkyloxy-phenyl-derivate
NO20023013D0 (no) Substituerte 8-arylkinolinfosfodiesterase-4-inhibitorer
NO20032807L (no) Substituerte 8-arylkinolin-fosfodiesterase-4-inhibitorer
DE50006096D1 (de) Herbizide mittel
NO20031332L (no) Arylalkan-sulfonamider med endothelin-antagonistaktivitet
TR200002893A3 (tr) Kinolin-4-il türevleri II
DE50006616D1 (de) Zange
ATE506357T1 (de) Heterocyclische aminoalkylpyridinderivate als psychopharmaka
ATE281436T1 (de) Chinolin-4-yl-derivate
DK1088818T3 (da) Quinolin-4-yl-derivater
ATE367379T1 (de) Quinolin-derivate als antientzündungsmittel
NO20022682L (no) Heterosykliske derivater
DE50104434D1 (de) Lactam-substituierte pyrazolopyridinderivate
IS2647B (is) Tetrahýdrókínólín afleiður
IS7870A (is) Tetrahýdrókínólín afleiður

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees